Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Studies of colorectal cancer screening by multitarget stool DNA (MT-sDNA) show false-positive (FP) rates of 7% to 13%. It is unclear whether FP patients are at increased long-term risk of adverse outcomes. Methods: We compared subsequent clinical events among patients with apparent FP MT-sDNA with those in patients reported as true negative (TN). This was a retrospective cohort study of participants in pre-FDA approval MT-sDNA studies having nonadvanced or negative baseline colonoscopy findings from a single referral center. Per-protocol and calibrated cutoffs defined FP and TN groups. From the time of stool collection, we measured differences between FP and TN groups in time to death, subsequent cancer diagnosis, and onset of alarm symptoms. Results: Of 1,050 eligible patients, only 6 were lost to follow-up. Median age was 65.6 years [interquartile range (IQR), 56.8–72.3]; 54% were female. Median follow-up time was 4 years (IQR, 3.5–5.3). Eight aerodigestive (lung and gastrointestinal tract) cancers occurred. FP status by calibrated, but not per-protocol, cutoffs was associated with subsequent aerodigestive cancer; however, cumulative incidence did not exceed SEER expectations from the general population. By any cutoff method, FP status was not associated with mortality or alarm symptoms. Conclusions: Although FP status was associated with long-term aerodigestive cancers, new cases were not temporally related and did not exceed incidence estimates from general population. Impact: These observations do not justify aggressive follow-up evaluation for patients with FP MT-sDNA at this time. Larger studies are needed to confirm these early findings. Cancer Epidemiol Biomarkers Prev; 26(4); 614–21. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., García, F. A. R., Gillman, M. W., Harper, D. M., Kemper, A. R., et al. (2016) · JAMA · doi:10.1001/jama.2016.5989 · Cited by 2,509
Multitarget Stool DNA Testing for Colorectal-Cancer Screening
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., Ahlquist, D. A., & Berger, B. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311194 · Cited by 1,900 · cited 8×
“In the cross-sectional screening studies (9, 10), MT-sDNA sensitivities for colorectal cancer were 92% to 100% and for adenomas 1, >1, 2, and 3 cmwere 40% to 42%, 51 to 52%, 62% to 66%, and 68% to 80%, respectively.”
BackgroundMethodInfluentialSelf-citationLong-term colorectal-cancer incidence and mortality after lower endoscopy
Nishihara, R., Wu, K., Lochhead, P., Morikawa, T., Liao, X., Qian, Z. R., Inamura, K., Kim, S. A., Kuchiba, A., Yamauchi, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301969 · Cited by 1,483
Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784 · cited 1×
“There is no population-level screening for other aerodigestive cancers, but even those at risk for familial pancreatic cancer might be offered only annual surveillance (25).”
BackgroundNext-Generation Stool DNA Test Accurately Detects Colorectal Cancer and Large Adenomas
Ahlquist, D. A., Zou, H., Domanico, M., Mahoney, D. W., Yab, T. C., Taylor, W. R., Butz, M. L., Thibodeau, S. N., Rabeneck, L., Paszat, L. F., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.031 · Cited by 315 · cited 1×
“A logistic algorithm converts quantitative data from these component assays into a binomial "positive" or "negative" result, and a false-positive (FP) rate approximating 10% was prespecified in development studies (11, 12).”
MethodSelf-citationClinical Performance of an Automated Stool DNA Assay for Detection of Colorectal Neoplasia
Lidgard, G. P., Domanico, M. J., Bruinsma, J. J., Light, J., Gagrat, Z. D., Oldham–Haltom, R. L., Fourrier, K. D., Allawi, H., Yab, T. C., Taylor, W. R., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.023 · Cited by 136 · cited 4×
“FP, n (%) 113 (11) 53 (11) 25 (11) 35 (10) 1.”
BackgroundMethodInfluentialSelf-citationStool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People
Redwood, D. G., Asay, E. D., Blake, I. D., Sacco, P. E., Christensen, C. M., Sacco, F. D., Tiesinga, J. J., Devens, M. E., Alberts, S. R., Mahoney, D. W., et al. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.10.008 · Cited by 107
Self-citation
Cited by
Wolf, A. M. D., Fontham, E. T. H., Church, T. R., Flowers, C. R., Guerra, C. E., LaMonte, S. J., Etzioni, R., McKenna, M. T., Oeffinger, K. C., Shih, Y. T., et al. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21457 · Cited by 1,944
“In 2 follow-up studies of patients with false-positive results on mt-sDNA with median follow-up of approximately 4 years, no excess rates of CRC or aero-digestive malignancies were identified.(122,123) In a more recent study by Cooper et al that included follow-up mt-sDNA, colonoscopy and upper endoscopy among 12 pati…”
BackgroundACG Clinical Guidelines: Colorectal Cancer Screening 2021
Shaukat, A., Kahi, C. J., Burke, C. A., Rabeneck, L., Sauer, B. G., & Rex, D. K. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001122 · Cited by 853
Current and future colorectal cancer screening strategies
Shaukat, A., & Levin, T. R. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00612-y · Cited by 516
Current Status and Emerging Trends in Colorectal Cancer Screening and Diagnostics
Beniwal, S., Lamo, P., Kaushik, A., Lorenzo-Villegas, D., Liu, Y., & MohanaSundaram, A. (2023) · Biosensors · doi:10.3390/bios13100926 · Cited by 60
“Despite the numerous advantages of stool tests, this diagnostic modality demonstrates a sensitivity of only 42% in detecting advanced polyps [25].”
Background
Metadata
- Authors
- Cotter, T. G., Burger, K. N., Devens, M. E., Simonson, J. A., Lowrie, K. L., Heigh, R. I., Mahoney, D. W., Johnson, D. H., Ahlquist, D. A., & Kisiel, J. B.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2017-04-01
- Volume
- 26
- Issue
- 4
- Pages
- 614-621
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2563111510
- Cited by
- 37
- References
- 8
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study. https://app.cochat.ai/papers/10.1158/1055-9965.epi-16-0800
- The paper
- Cotter, T. G., Burger, K. N., Devens, M. E., Simonson, J. A., Lowrie, K. L., Heigh, R. I., Mahoney, D. W., Johnson, D. H., Ahlquist, D. A., & Kisiel, J. B. (2017). Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-16-0800
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.